Clinical Value of Circulating Lipocalins and Insulin-Like Growth Factor Axis in Pancreatic Cancer Diagnosis

El‐Mesallamy, Hala O.; Hamdy, Nadia M.; zaghloul, Ashraf; Sallam, Al-Aliaa M.

doi:10.1097/mpa.0b013e3182550d9d

Cited by 30 publications

(20 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were seven nested case-control studies [21,22,29,30,31,32,33,34] and three retrospective case-control studies [23,24,25]. Nine articles described the association between IGF-I concentration and PaC risk [21,22,23,24,25,30,31,32,33], three described the association between IGF-II concentration and PaC risk [22,30,31], six reported the association between IGFBP-3 concentration and PaC risk [21,22,30,31,32,33], while four reported the association between the IGF-I/IGFBP-3 ratio and PaC risk [21,22,30,32]. The average score for the quality assessment of included studies was 7.9 (Table 1).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Serum Insulin-Like Growth Factor Axis and the Risk of Pancreatic Cancer: Systematic Review and Meta-Analysis

et al. 2017

View full text Add to dashboard Cite

Objective: To investigate the association between serum concentration of insulin-like growth factor (IGF) and the risk of pancreatic cancer (PaC). Methods: We identified eligible studies in Medline and EMBASE databases (no reference trials from 2014 to 2016) in addition to the reference lists of original studies and review articles on this topic. A summary of relative risks with 95% confidence intervals (CI) was calculated using a random-effects model. The heterogeneity between studies was assessed using Cochran Q and I2 statistics. Results: Ten studies (seven nested case-control studies and three retrospective case-control studies) were selected as they met our inclusion criteria in this meta-analysis. All these studies were published between 1997 and 2013. The current data suggested that serum concentrations of IGF-I, IGF-II and insulin-like growth factor binding protein-3 (IGFBP-3)in addition to the IGF-I/IGFBP-3 ratio were not associated with an increased risk of PaC (Summary relative risks (SRRs) = 0.92, 95% CI: 0.67–1.16 for IGF-I; SRRs = 0.84, 95% CI: 0.54–1.15 for IGF-II; SRRs = 0.93, 95% CI: 0.69–1.17 for IGFBP-3; SRRs = 0.97, 95% CI: 0.71–1.23 for IGF-I/IGFBP-3 ratio). There was no publication bias in the present meta-analysis. Conclusion: Serum concentrations of IGF-I, IGF-II, IGFBP-1 and IGFBP-3 as well as the IGF-I/IGFBP-3 ratio were not associated with increased risk of PaC.

show abstract

Section: Resultsmentioning

confidence: 99%

“…We transformed the corresponding CIs into the log RRs, using the Greenland formula to calculate the corresponding variances. For studies that lacked estimates, we calculated crude estimates from tabular data [23,24,25]. We pooled these relative risks using a fixed effects model to get a summary relative risk for further meta-analysis.…”

Section: Methodsmentioning

confidence: 99%

Serum Insulin-Like Growth Factor Axis and the Risk of Pancreatic Cancer: Systematic Review and Meta-Analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Among the different growth factors influencing the initiation, progression, and metastasis of gastric cancer, IGF plays a critical role in the stimulation of gastric cancer cell proliferation, survival, angiogenesis, and resistance to apoptosis [41]. Recent studies have shown that elevation of serum IGF-1 increases the risk for developing several types of cancer [41][42][43]. In gastric cancer, aberrant activation of IGF-1 receptor by autocrine/paracrine loops has been suggested because expression of both IGF and its receptor is high in tumor tissue.…”

Section: Discussionmentioning

confidence: 99%

RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells

et al. 2014

View full text Add to dashboard Cite

Background ST6GalNAc I is a sialyltransferase controlling the expression of sialyl-Tn antigen (STn), which is overexpressed in several epithelial cancers, including gastric cancer, and is highly correlated with cancer metastasis. However, the functional contribution of ST6GalNAc I to development or progression of gastric cancer remains unclear. In this study, we investigated the effects of suppression of ST6GalNAc I on gastric cancer in vitro and in vivo. Methods Gastric cancer cell lines were transfected with ST6GalNAc I siRNA and were examined by cell proliferation, migration, and invasion assays. We also evaluated the effect of ST6GalNAc I siRNA treatment in a peritoneal dissemination mouse model. The differences in mRNA levels of selected signaling molecules were analyzed by polymerase chain reaction (PCR) arrays associated with tumor metastasis in MKN45 cells. The signal transducer and activator of transcription 5b (STAT5b) signaling pathways that reportedly regulate the insulin-like growth factor-1 (IGF-1) were analyzed by Western blot.

show abstract

“…As previously demonstrated for many tumor pancreatic cancer markers, MIC-1 also showed only a modest ability to distinguish between pancreatic cancer and pancreatitis and had a limited value in the early diagnosis of PDAC [66]. A small group of patients with pancreatic cancer and preexisting type 2 diabetes demonstrated significant elevation in the serum levels of retinol binding protein 4 (RBP-4), NGAL (neutrophil gelatinase B-associated lipocalin) and insulin-like growth factor 1 (IGF-1) together with a significant reduction in the level of insulin-like growth factor I binding protein 3 (IGFBP-3); receiver operating characteristic curve analysis revealed that theses markers could distinguish pancreatic cancer from non-pancreatic cancer cases in this study [67]. Furthermore, IGF-1R as well as IGF-1 and IGF-2 were found to be up-regulated in pancreatic cancer [68].…”

Section: Selected Markers For Early Detection Of Pancreatic Cancermentioning

confidence: 86%

Diagnostic value of selected markers and apoptotic pathways for pancreatic cancer

Słotwiński¹,

Słotwińska²

2016

cejoi

View full text Add to dashboard Cite

Pancreatic cancer occupies the fourth place as a cause of death from cancer, and the mortality rate is similar to the number of newly detected cases. Due to the late diagnosis, only 5-6% of patients with pancreatic cancer survive for five years. Given that early diagnosis is critical for improving patients’ survival rates, there is an urgent need for the discovery and validation of new biomarkers with sufficient sensitivity and specificity to help diagnose pancreatic cancer early. Detection of serum tumor markers (CA19-9, CEA, CA125 and CA242) is conducive to the early diagnosis of pancreatic cancer. The combination of miR-16, miR-196a and CA19-9 plasma level was more effective, especially in early tumor screening. Furthermore, recent studies reported that mainly miR-21, miR-155 and miR-196 were dysregulated in IPMN (intraductal papillary mucinous neoplasms) and PanIN (pancreatic intraepithelial neoplasia) lesions, suggesting their usefulness as early biomarkers of these diseases. The reduced rate of apoptosis plays a crucial role in carcinogenesis, and it is one of the most important characteristics acquired by pancreatic cancer cells, which protects them from attack by the immune system and reduces the effectiveness of pharmacological treatment. This review summarizes the data concerning the clinical utility of selected biomarkers in pancreatic cancer patients. The review mainly focuses on the genetic aspects of signaling pathway disorders associated with apoptosis in the pathogenesis and diagnosis of pancreatic cancer.

show abstract

Clinical Value of Circulating Lipocalins and Insulin-Like Growth Factor Axis in Pancreatic Cancer Diagnosis

Abstract: Retinol binding protein 4, NGAL, IGF-I, and IGFBP-3 are associated with PC in type 2 diabetic patients. They could be useful in distinguishing PC from non-PC cases when used in combination or with cancer antigen.

Cited by 30 publications

References 29 publications

Serum Insulin-Like Growth Factor Axis and the Risk of Pancreatic Cancer: Systematic Review and Meta-Analysis

Serum Insulin-Like Growth Factor Axis and the Risk of Pancreatic Cancer: Systematic Review and Meta-Analysis

RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells

Diagnostic value of selected markers and apoptotic pathways for pancreatic cancer

Contact Info

Product

Resources

About